JPMorgan Chase & Co. Raises Cytokinetics (NASDAQ:CYTK) Price Target to $103.00
JPMorgan Chase & Co. has increased its price target for Cytokinetics (NASDAQ:CYTK) to $103.00 from $97.00, reiterating an "overweight" rating and suggesting a 37.04% upside. This comes as Cytokinetics shares dipped slightly despite the company surpassing EPS and revenue expectations. Analyst sentiment remains largely …